Fig. S1.
OPB-51602 interferes with STAT3 signaling in cancer cells. (A) Immunoblot analysis of STAT3 and pSTAT3 in H358 and LNCaP cells treated with OPB-51602. (B and C) STAT3 and pSTAT3 in H358 cells treated with OPB-51602 and the indicated compounds for 16 h in FM or CM. (D) STAT3 and pSTAT3 in DU145 cells treated with NVP-BSK805 for 16 h in FM or CM. (E) Amino acids (red) in the OPB-51602 (blue) binding site in the STAT3 SH2D (Upper) and per residue energy decomposition analysis (Lower) of the complex.